Combo Pill for Urinary Incontinence Gets FDA Approval: Mirabegron + Solifenacin | Pharma Letter

Quick Summary

  • FDA has approved mirabegron (Myrbetriq, Astellas Pharma) in combination with the solifenacin succinate for the treatment of overactive bladder (OAB)
  • Mirabegron is a beta-3 agonist and solifenacin is a muscarinic antagonist

 

Background

  • Both drugs had been previously approved for OAB monotherapy

 

Source: FDA approves sNDA for Myrbetriq combo

Advertisements